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Abstract: Chemoenzymatic and enzymatic cascade reactions
enable the synthesis of complex stereocomplementary 1,3,4-
trisubstituted tetrahydroisoquinolines (THIQs) with three
chiral centers in a step-efficient and selective manner without
intermediate purification. The cascade employs inexpensive
substrates (3-hydroxybenzaldehyde and pyruvate), and
involves a carboligation step, a subsequent transamination,
and finally a Pictet–Spengler reaction with a carbonyl cosub-
strate. Appropriate selection of the carboligase and trans-
aminase enzymes enabled the biocatalytic formation of
(1R,2S)-metaraminol. Subsequent cyclization catalyzed either
enzymatically by a norcoclaurine synthase or chemically by
phosphate resulted in opposite stereoselectivities in the prod-
ucts at the C1 position, thus providing access to both
orientations of the THIQ C1 substituent. This highlights the
importance of selecting from both chemo- and biocatalysts for
optimal results.
The tetrahydroisoquinoline (THIQ) moiety is a “privileged
scaffold”,[1] and as such, it is found in numerous bioactive
natural products (e.g., noscapine,[2] dioncophyllines[3]) and
synthetic pharmaceutical drugs (e.g., solifenacin[4]). THIQ-
containing compounds demonstrate a wide range of bioac-
tivities, including antitumor,[2] antiparasitic,[3] and anticholi-
nergic[4] properties.
Naturally derived THIQs may be obtained by extraction
or fermentation,[5] but in many cases, only small quantities are
available, typically as one component of a mixture. Chemical
syntheses are a frequent source of these compounds, but
complex multistep asymmetric routes that give high stereo-
selectivities can be challenging, including at scale, and are
often dependent on the use of toxic or environmentally
harmful chemicals.[6] Therefore, novel synthetic routes
towards THIQs are of significant interest.
In vitro biocatalysis provides a viable method of produc-
ing complex THIQs in high stereoselectivities and under mild
conditions.[7–9] Previous studies have shown norcoclaurine
synthase (NCS), the Pictet–Spenglerase from plant benzyl-
isoquinoline alkaloid biosynthesis,[10,11] to be a versatile
biocatalyst. NCS can convert 3-hydroxyphenethylamines
(e.g., dopamine) and a carbonyl cosubstrate into a (1S)-
THIQ with high stereoselectivities.[12-15] The enzyme has
demonstrated a remarkably wide carbonyl cosubstrate toler-
ance, accepting a variety of aldehydes and ketones.[13-20]
NCS has also been successfully employed in chemoenzy-
matic cascades.[12,15, 16, 21] As an alternative to NCS, inorganic
phosphate can be used to catalyze the Pictet–Spengler
reaction (PSR), typically forming racemic THIQs under
aqueous conditions.[22] This can be successfully combined with
enzyme steps.[21]
Modular biocatalytic cascades[23] for the stereoselective
production of pharmaceutical compounds are exemplified by
the work conducted on phenylpropanolamines.[24–26] All four
possible isomers of nor(pseudo)ephedrine are available from
simple starting materials by one-pot two-enzyme cascades
when appropriate biocatalysts are selected.[26] Phenylpropa-
nolamines with an additional 3-hydroxy group on the
aromatic ring have been considered to be suitable substrates
for cascades including PSRs catalyzed by NCS or phosphate.
Indeed, a previous screen of Coptis japonica NCS (CjNCS2)
had suggested that (1R,2S)-2-amino-1-(3-hydroxyphenyl)pro-
pan-1-ol (also referred to as metaraminol) was accepted as
a substrate, and gave the corresponding product in low
yield.[13] With this in mind, two three-step cascades, using
either three enzymes or two enzymes and one non-enzymatic
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step, were designed for the stereoselective formation of 1,3,4-
trisubstituted THIQs (Scheme 1).
Herein, we present the first three-step (chemo)enzymatic
cascades for the stereoselective formation of 1,3,4-trisubsti-
tuted THIQs from inexpensive starting materials. The cas-
cades begin with a carboligation using 3-hydroxybenzalde-
hyde (1; Scheme 1) and pyruvate to form acyloin 2 ; subse-
quent transamination gives rise to 2-amino-1-(3-hydroxyphe-
nyl)propan-1-ol (3), which can then undergo a PSR with
a carbonyl cosubstrate. Most importantly, NCS and phosphate
catalysis of the PSR step result in opposite stereoselectivities,
thus providing access to both orientations of the THIQ C1
substituent, which highlights the importance of selecting from
both chemo- and biocatalysts.
The first requirement for chemoenzymatic cascades
towards complex trisubstituted THIQs was the development
of a two-step cascade for the production of the amino alcohol
(1R,2S)-3 (Scheme 1). The initial step in the cascade was the
carboligation of 3-hydroxybenzaldehyde (1) and acetalde-
hyde (after decarboxylation from pyruvate) to form (R)-1-
hydroxy-1-(3-hydroxyphenyl)propan-2-one ((R)-2). This was
catalyzed by the ThDP-dependent acetohydroxy acid syntha-
se I from Escherichia coli (EcAHAS-I),[27] which was also
capable of catalyzing the decarboxylation of pyruvate to
acetaldehyde prior to carboligation in the same active site.
After 1 hour incubation, the reaction was complete with
excellent conversions (conversion 95%, yield 95: 2%) and
excellent enantioselectivities (ee 99%). To form (1R,2S)-3,
the hydroxyketone intermediate (R)-2 was immediately
subjected to transamination with the transaminase from
Chromobacterium violaceum (Cv2025)[28] using isopropyl-
amine as the amine donor.
This step was complete in 8 hours and provided excellent
conversion (conversion 93: 1%, yield 91: 3%) and excel-
lent isomeric content of one isomer over all possible isomers
(97: 1%; for the ic definition, see the Supporting Informa-
tion, Section S5). The enzymes described for this two-step
cascade have been valuable catalysts for cascade reactions
with unsubstituted aromatic aldehydes and hydroxyke-
tones.[25, 29] Here, they also proved to be suitable catalysts for
a substituted benzaldehyde, yielding biocatalytic access to
(1R,2S)-3 (metaraminol), an a1 adrenergic receptor agonist
that acts as a vasoconstrictor.[30]
Compound 3 was then used for a subsequent PSR. A vital
feature of 3 is the presence of the meta-hydroxy group, which
is mechanistically required for both the mild phosphate-
catalyzed and the enzyme-catalyzed PSR.[22,31] The carbonyl
cosubstrate phenylacetaldehyde (4) was selected as a repre-
sentative aldehyde for the proof-of-principle reactions using
NCSs. NCS wild-type enzymes from Coptis japonica and
Thalictrum flavum and available variants were screened
against 3 and 4, and the formation of products was monitored
by HPLC analysis (see the Supporting Information, Sec-
tion S6 for details). The variant TfNCS-A79I was found to
produce the largest quantity of product. In a recent study, this
variant had also demonstrated increased conversion com-
pared to the wild-type enzyme for reactions with dopamine
and ketones.[18] Therefore, TfNCS-A79I was selected for
a preparative (50 mmol) biotransformation reaction for prod-
uct identification, using 4 and (1R,2S)-3 from a commercial
source. The THIQ product (1S,3S,4R)-1-benzyl-3-methyl-
1,2,3,4-tetrahydroisoquinoline-4,6-diol (5) was isolated in
excellent yield (92%, 5·HCl) and purity (de 99%). Analysis
by both HPLC on a chiral stationary phase and two-dimen-
Scheme 1. a) Enzymatic and b) chemoenzymatic three-step cascades to isoquinoline derivatives. Reaction conditions: step 1: 100 mm HEPES,
pH 7.5, 5 mm MgCl2, 0.1 mm ThDP, 0.05 mm FAD, 10 mm 1, 20 mm sodium pyruvate, 2.5% DMSO (v/v), 0.5 mgmL
@1 acetohydroxy acid
synthase I from Escherichia coli (EcAHAS-I), 30 8C, 750 rpm; step 2: 0.2 mm PLP, 100 mm IPA, 3.1% DMSO (v/v), 3 mgmL@1 transaminase from
Chromobacterium violaceum (Cv2025), 30 8C, 750 rpm; step 3a: 9.5 mm 4, 2.5% DMSO (v/v), 0.5 mgmL@1 norcoclaurine synthase variant from
Thalictrum flavum (DTfNCS-A79I), 37 8C, 750 rpm; step 3b: 10 mm 6, 200 mm potassium phosphate buffer, pH 7, 50 8C, 750 rpm. For more
detailed information on the set-up, see Section S2.
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sional NMR spectroscopy confirmed the presence of
(1S,3S,4R)-5 (see Section S4.1).
With the isolated product 5 and analytical data for the
isolated stereoisomer as well as a suitable separation method
for all possible stereoisomers in hand (Section S3), the entire
three-step three-enzyme cascade was demonstrated. As
described above and shown in Scheme 1, (1R,2S)-3 was
formed biocatalytically from 3-hydroxybenzaldehyde (1),
pyruvate (2), and isopropylamine in two enzyme-catalyzed
steps. Subsequently, TfNCS-A79I and 4 were added. The
conversions and stereoselectivities for this last step were
excellent (conversion 99: 1%, dc > 99%). Overall the
cascade conversion of 1 into (1S,3S,4R)-5 was achieved in
88% yield (calculated from substrate depletion; Section S8
and Figure 39), with excellent optical purities after each step
(Scheme 1a; only one product, the desired one, was identified
by HPLC and GC-TOF-MS analysis; see Section S3 and
Figures S8d and S12). The final ic value was > 97%. This
formation of a complex trisubstituted THIQ, with the highly
selective installation of three chiral centers, high reaction
yields, and no intermediate purification, is a clear demon-
stration of the power of biocatalytic cascades for the
production of complex molecules. What is crucial to note in
this case is that NCS is a particularly promiscuous enzyme
with respect to the carbonyl cosubstrate, with no observed
loss in stereoselectivity,[13–15] and therefore, this cascade can be
easily adapted to produce a wide variety of 1S-configured
THIQs.
The PSR of meta-hydroxyphenylethylamines and alde-
hydes can also be very effectively catalyzed by inorganic
phosphate.[22] In the initial screening with (1R,2S)-3 and 4
(which was selected for the three-step enzyme cascade),
phosphate catalysis was observed to give rise to three
products (Section S3.4), where one of the minor products
was (1S,3S,4R)-5. To probe the stereoselectivity of the
phosphate-catalyzed PSR, various other aldehydes were
examined. A number of carbonyl cosubstrates were screened,
and the product selectivities were monitored (Section S7).
The use of more sterically demanding aldehydes increased the
reaction selectivities immensely. Notably, the aldehyde
2-bromobenzaldehyde (6) provided the best stereoselectivity
in the product. (Although priority naming rules dictate the
major product here to be an (1S)-THIQ, the configuration of
the C1 stereocenter is opposite to that of THIQs produced by
NCS.) To isolate and characterize the product (1S,3S,4R)-1-
(2-bromophenyl)-1,2,3,4-tetrahydroisoquinoline-4,6-diol (7),
this reaction was scaled up (20 mmol), and the product was
purified by extraction and recrystallization to give 7·HCl in
54% yield (97% de) after isolation. Analysis by both HPLC
on a chiral stationary phase and two-dimensional NMR
spectroscopy confirmed the compound to be (1S,3S,4R)-7
(97% de before recrystallization, 99% de after recrystalliza-
tion; see Section 4.2).
The three-step chemoenzymatic cascade was then per-
formed (Scheme 1b). After the amino alcohol (1R,2S)-3 had
been formed in two enzyme-catalyzed steps as described
above, the enzymes were removed by ultrafiltration, and
potassium phosphate and 6 were added. This final step
proceeded with high conversions (85%, 24 h) and excellent
stereoselectivities (dc 99%; Section 3.5 and Figure S9c). The
major product of the cascade was the anticipated (1S,3S,4R)-
1-(2-bromophenyl)-3-methyl-1,2,3,4-tetrahydroisoquinoline-
4,6-diol (7). Minor side products were also formed; these are
believed to be the ortho-cyclized products 1-(2-bromo-
phenyl)-3-methyl-1,2,3,4-tetra-hydroisoquinoline-4,8-diol
(< 4%, see Sections S3.5 and 4.3; validated by GC-TOF-MS,
HPLC, and NMR analysis by correlation to the non-cascade
KPi reaction products).[16] Overall, the conversion of the
cascade from 1 to (1S,3S,4R)-7 was 77%, based on the
substrate depletion of each step. Again, the final ic value was
excellent (> 97%). The enzymatic synthesis of the opposite
stereoisomer (1R,3S,4R)-7 was not possible as the NCS
enzymes screened did not accept the sterically demanding
aldehyde 2-bromobenzaldehyde as a substrate.
The high stereoselectivity of the phosphate-catalyzed PSR
reaction with (1R,2S)-3 can be explained by the three-
dimensional structure of the phenethylamine substrate. In
the transition state of the phosphate PSR cyclization step, the
molecule likely adopts a pseudo-chair conformation with the
aldehyde R group occupying a pseudo-equatorial orientation
(Figure 1). In the phosphate-catalyzed reaction, the favored
transition state also has the methyl and hydroxy substituents
in pseudo-equatorial positions. Bulkier aldehyde substituents
increase the stereoselectivity, presumably owing to increased
steric hindrance and an increase in the energy of the less
favored transition state (in which the methyl and hydroxy
groups are pseudo-axial). This is an example of substrate-
controlled diastereoselectivity, in which the existing stereo-
centers determine the installed stereocenter. The enzymes
EcAHAS-I and Cv2025 thus establish the stereocenters in the
amino alcohol (3), which in turn determine the THIQ C1
stereocenter. It is pertinent to note that the THIQ C1
configuration available with the phosphate-catalyzed method
here is opposite to that obtained with NCS. Thus the
phosphate-mediated PSR provides direct access to “unnatu-
ral” THIQ stereoisomers, without the requirement for
discovering or engineering a novel NCS with inverted
stereoselectivity.
The substrate-controlled outcome of the phosphate-
catalyzed reaction contrasts with the catalyst-controlled
stereoselectivity in the enzyme-catalyzed reactions. In con-
trast to some transaminases and imine reductases,[32,33] for
which changing stereopreference, depending on the selected
substrates and cosubstrates, has been described, NCS can only
stabilize one transition state owing to the arrangement of the
active-site side chains, giving rise to only (1S)-THIQs
(Figure 1).[13, 14,34] In this transition state, the aldehyde-derived
substituent is pseudo-equatorial and oriented towards the
active-site entrance while the methyl and hydroxy substitu-
ents are in pseudo-axial positions. In this scenario, the
constraints of the biocatalyst active-site architecture over-
whelm any conformational preferences of the intermediate.
Whereas the phosphate- and enzyme-catalyzed reactions
provide access to the opposite configurations at C1 in the PSR
with (1R,2S)-3, the aldehyde cosubstrates required for
maximum conversion and stereoselectivity differ. Aldehyde
4, an excellent substrate for NCS, seems to be “insufficiently
bulky” to provide good selectivity in the phosphate-catalyzed
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variant. Conversely, more sterically demanding 2-bromoben-
zaldehyde (6) is an excellent cosubstrate in the stereoselective
phosphate-catalyzed reaction; however, it is not accepted by
NCS wild-type enzymes or variants thereof. Future catalyst
engineering of either phosphate or NCS would help increase
the overlap of suitable aldehyde cosubstrates. Synthesizing
bulkier phosphate catalysts to improve the stereoselectivity
for other aldehydes[35] and enzyme engineering of NCS to
improve substrate tolerance towards bulkier aldehydes[14]
could expand the range of this system further.
A crucial feature of the cascade systems for the produc-
tion of phenylpropanolamines is enzyme modularity, which
principally enables the construction of all four isomers by
carboligases and transaminases with complementary stereo-
selectivity (see Section S6). Such an approach will be taken in
future work with all stereoisomers of the 3-hydroxy-substi-
tuted hydroxyketone intermediate 3, and these isomers will
be examined with phosphate and NCS in PSRs to form novel
1,3,4-trisubstituted THIQs. Furthermore, in a successful sub-
strate screening with aldehydes, further reaction partners
were identified to create a large THIQ library (see Sec-
tion S7).
In conclusion, we have demonstrated the applicability of
chemoenzymatic and enzymatic cascades for the formation of
complex chiral compounds bearing three chiral centers from
low-cost starting materials in a rapid and selective manner
without intermediate purification. The stereocomplementary
PSRs resulting from chemical or enzymatic catalysis highlight
how (aqueous-based) chemical processes can work in partner-
ship with biocatalysis. The diversity of THIQs accessible by
biocatalysis has now been expanded significantly.
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